drugset / Trial / NCT05939076

First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation

NCT05939076

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this multicentre, prospective, randomized, open, blinded for evaluation of end point (PROBE) controlled parallel-group superiority trial, is to compare the efficacy of antiarrhythmic drug (AAD) therapy and cryoballoon pulmonary vein isolation (PVI) regarding freedom from atrial fibrillation (%) assessed by an implantable cardiac monitor (ICM), ECG tracing or Holter at 12 months in patients with persistent AF. The main question\[s\] it aims to answer are: * Will first-line cryoballoon ablation for PVI compared to AAD, result in 25 % higher freedom from atrial tachyarrhythmias lasting \> 6 minutes at 12 months (primary outcome) excluding three months initial blanking period, in patients with symptomatic and recurrent persistent AF? * Will first-line cryoablation for PVI, compared to AAD result in a superior improvement in health related Quality of Life (HRQoL), AF/AT burden, AF/AT progression and reversion, more reverse atrial remodeling, cognitive function, healthcare utilization with associated costs, better safety, at 12-24-36 months as compared with drug use? Participants will be randomized 1:1 to first-line PVI using the cryoballoon or to first-line antiarrhythmic drug therapy and during 3 years follow-up undergo regular; * Continuous ECG monitoring for assessment of first AF recurrence and AF burden using an implantable cardiac monitor, * Regular echocardiographic exams for reverse atrial remodelling assessment, * HRQoL questionnaires * Assessment of cognitive function * Atrial fibrillation evaluation regarding structured characterisation and AF progression/regression * Assessment of Health care use and costs * Safety

Timeline

Start
2023-08-21
Primary completion
2027-12
Completion
2028-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dronedarone Small molecule 400 mg Oral
Comparator flecainide Small molecule 50 mg Oral
Comparator flecainide Small molecule 100 mg Oral
Comparator flecainide Small molecule 200 mg Oral
Comparator propafenone Unknown 150 mg Oral
Comparator propafenone Unknown 300 mg Oral
Comparator sotalol Small molecule 80 mg Oral
Comparator sotalol Small molecule 160 mg Oral